The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 761-769

  Manvich, Daniel F ^a   Kimmel, Heather L ^a,b   Cooper, Debra A ^a   Howell, Leonard L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; COCAINE; DOPAMINE; SEROTONIN 2C ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; DRUG INFUSION; DRUG SELF ADMINISTRATION; IN VIVO STUDY; INSTRUMENTAL CONDITIONING; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; SPECIES; SQUIRREL MONKEY;

AMINOPYRIDINES; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; DOPAMINE; DRUG SYNERGISM; INDOLES; MALE; RECEPTOR, SEROTONIN, 5-HT2C; SAIMIRI; SELF ADMINISTRATION; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SUBSTANCE-RELATED DISORDERS;

EID: 84865170085     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.195156     Document Type: Article

References (43)

1. Alex KD and Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320. (Pubitemid 46149046)
2. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, and Pehek EA (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242-251. (Pubitemid 40256305)
3. 3 receptor activation on the behavioral-stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys. Pharmacology 83:164-169.
4. Bauzo RM, Kimmel HL, and Howell LL (2009) Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys. Pharmacol Biochem Behav 94:204-210.
5. Brady KT and Verduin ML (2005) Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Subst Use Misuse 40:2021-2041, 2043-2048.
6. Bubar MJ and Cunningham KA (2008) Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res 172:319-346.
7. Burghardt NS, Bush DE, McEwen BS, and LeDoux JE (2007) Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT2C receptor antagonist. Biol Psychiatry 62:1111-1118. (Pubitemid 350029715)
8. 2C receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 29:1782-1789.
9. Czoty PW, Justice JB Jr, and Howell LL (2000) Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys. Psychopharmacology (Berl) 148:299-306. (Pubitemid 30136737)
10. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241. (Pubitemid 38451889)
11. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, Sharp T, Daszuta A, Soumier A, Papp M, et al. (2008) S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 199:549-568.
12. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
13. Di Giovanni G, De Deurwaerdére P, Di Mascio M, Di Matteo V, Esposito E, and Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587-597. (Pubitemid 29193268)
14. Di Giovanni G, Di Matteo V, Di Mascio M, and Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61.
15. Di Matteo V, Di Giovanni G, Di Mascio M, and Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195-1205. (Pubitemid 29292408)
16. Fantegrossi WE, Bauzo RM, Manvich DM, Morales JC, Votaw JR, Goodman MM, and Howell LL (2009) Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology (Berl) 205:337-347.
17. Filip M, Bubar MJ, and Cunningham KA (2004) Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 310:1246-1254. (Pubitemid 39108947)
18. 2A receptor antagonist M100907 and the 5-HT2C receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaineinduced reinstatement of responding. Neuropsychopharmacology 27:576-586.
19. Fletcher PJ, Sinyard J, and Higgins GA (2006) The effects of the 5-HT2C receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) 187:515-525. (Pubitemid 44200523)
20. Ginsburg BC, Kimmel HL, Carroll FI, Goodman MM, and Howell LL (2005) Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacol Biochem Behav 80:481-491. (Pubitemid 40299350)
21. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, and Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221. (Pubitemid 30252995)
22. Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, Ishibashi K, and Matsuoka N (2006) Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 553:171-184. (Pubitemid 44779607)
23. Hensler JG (2006) Serotonergic modulation of the limbic system. Neurosci Biobehav Rev 30:203-214.
24. Howell LL and Byrd LD (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275:1551-1559. (Pubitemid 26129947)
25. Hoyer D, Hannon JP, and Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554. (Pubitemid 34219205)
26. Jones BJ and Blackburn TP (2002) The medical benefit of 5-HT research. Pharmacol Biochem Behav 71:555-568. (Pubitemid 34219206)
27. Kantor S, Jakus R, Molnar E, Gyongyosi N, Toth A, Detari L, and Bagdy G (2005) Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra. J Pharmacol Exp Ther 315:921-930. (Pubitemid 41500759)
28. Kimmel HL, Ginsburg BC, and Howell LL (2005) Changes in extracellular dopamine during cocaine self-administration in squirrel monkeys. Synapse 56:129-134.
29. Kimmel HL, Manvich DF, Blough BE, Negus SS, and Howell LL (2009) Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav 94:278-284.
30. Kimmel HL, O'Connor JA, Carroll FI, and Howell LL (2007) Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav 86:45-54. (Pubitemid 46274968)
31. Lee J, Jung ME, and Lee J (2010) 5-HT2C receptor modulators: a patent survey. Expert Opin Ther Pat 20:1429-1455.
32. 3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42:12-26.
33. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr., Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496. (Pubitemid 46025760)
34. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S.
35. Murphy TK, Segarra A, Storch EA, and Goodman WK (2008) SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 20:203-208. (Pubitemid 351489519)
36. Navailles S, De Deurwaerdère P, Porras G, and Spampinato U (2004) In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology 29:319-326. (Pubitemid 38175150)
37. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, and Nardi I (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601-611. (Pubitemid 29268048)
38. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, and Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518.
39. Rocha BA, Goulding EH, O'Dell LE, Mead AN, Coufal NG, Parsons LH, and Tecott LH (2002) Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 22:10039-10045. (Pubitemid 35332889)
40. Spealman RD, Barrett-Larimore RL, Rowlett JK, Platt DM, and Khroyan TV (1999) Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav 64:327-336. (Pubitemid 29438618)
41. Spealman RD, Madras BK, and Bergman J (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149. (Pubitemid 19261956)
42. Vaswani M, Linda FK, and Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102. (Pubitemid 36131110)
43. Zaniewska M, McCreary AC, and Filip M (2009) Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. Synapse 63:653-661.